MSI-H CANCER
Clinical trials for MSI-H CANCER explained in plain language.
Never miss a new study
Get alerted when new MSI-H CANCER trials appear
Sign up with your email to follow new studies for MSI-H CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a double immunotherapy beat standard care for a tough stomach cancer?
Disease control Recruiting nowThis phase II trial is comparing a new combination of two immunotherapies (iparomlimab and tuvonralimab) against standard chemotherapy plus a PD-1/PD-L1 inhibitor as a first-line treatment for people with recurrent or metastatic gastric cancer that is MSI-H or dMMR. The study aim…
Matched conditions: MSI-H CANCER
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new oral drug, MOMA-341, alone or with other treatments, in people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The main goal is to check safety and find the best dose. About 132 adults whose cancer has not responde…
Matched conditions: MSI-H CANCER
Phase: PHASE1 • Sponsor: MOMA Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new daily pill called NDI-219216 for people with advanced solid tumors that have not responded to standard treatments. The study will first check safety and side effects, then look at whether the drug can shrink tumors. About 134 participants w…
Matched conditions: MSI-H CANCER
Phase: PHASE1, PHASE2 • Sponsor: Nimbus Wadjet, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC